Highlights

  • On 24 July 2026 Cochlear confirmed its hearing implant systems will keep entering the US duty-free after the US Government's final Section 301 findings retained the relevant Harmonized Tariff Schedule classification.
  • The issue traces back to April 2025, when the US announced a 10% tariff on Australian exports; Cochlear said then that it expected to keep relying on a duty-free chapter of the US tariff schedule for hearing implants.
  • In FY2025 (year to 30 June 2025) Cochlear reported sales revenue of $2,355.8 million, statutory net profit of $388.9 million and underlying net profit of $391.6 million, with cochlear implant units up 12% to 53,968.
  • Management has guided to FY2026 underlying net profit of $435-460 million, implying 11-17% growth, supported by new products such as the Nucleus Nexa smart implant and Osia 3 sound processor.
  • Cochlear paid a full-year dividend of $4.30 per share and ended FY2025 with net cash of $275.7 million.
  • Reimbursement, competition, foreign-exchange movements and the still-evolving global trade environment remain the key risks to the outlook.

Cochlear (ASX: COH), the Sydney-based world leader in implantable hearing devices, has spent much of the past 18 months navigating a shifting United States trade landscape. On 24 July 2026 the company told the market that its hearing implant systems would continue to enter the US duty-free, after the US Government's final Section 301 investigation findings retained the tariff classification that shields the category from import duties. For a business that earns a large share of its revenue in the Americas and manufactures many of its implants in Australia, the confirmation removes a meaningful overhang. Yet trade policy is only one variable for a company whose fortunes rest on clinical innovation, reimbursement and steadily expanding access to hearing technology. The question for investors is whether Cochlear can convert a favourable trade outcome into sustained global momentum, or whether other pressures will temper the story.

A Trade Reprieve, Confirmed

The headline development is a favourable one. On 24 July 2026 Cochlear confirmed to the ASX that its hearing implant systems will continue to be imported into the United States duty-free, after the US Government's final Section 301 investigation findings retained the tariff classification that provides duty-free entry for hearing implants.

The episode dates back to early 2025. In April 2025, after Washington announced a 10% tariff on Australian exports effective 2 April 2025, Cochlear told the market it expected to keep relying on a chapter of the Harmonized Tariff Schedule of the United States that provides for duty-free importation on a range of products, including hearing implants.

The July 2026 confirmation therefore reflects the outcome of a formal review process rather than a fresh threat. The company has indicated it intends to keep engaging in global trade discussions to support policies that recognise the clinical need for, and economic benefits of, hearing implants.

In short, a potential cost headwind that had hung over the stock has, at least for now, been resolved in Cochlear's favour.

Inside the Hearing-Implant Franchise

Cochlear is one of Australia's best-known medical technology companies and the global pioneer of the multi-channel cochlear implant. Its products restore or improve hearing for people with severe to profound sensorineural hearing loss and other forms of hearing impairment.

The business is built around three segments. Cochlear Implants covers the Nucleus system, in which a surgically implanted device works with an external sound processor. Acoustics covers bone conduction and acoustic implant solutions, including the Baha and Osia ranges. Services generates recurring revenue from sound-processor upgrades, accessories and support delivered to the installed base of recipients over their lifetimes.

That recurring Services stream is a distinctive feature of the model: each implant recipient represents not only an upfront sale but a long-term relationship, as processors are periodically upgraded to newer technology.

Cochlear sells directly to clinics and hospitals across developed and emerging markets, and invests heavily in research and development to defend its technology leadership against a small number of global competitors.

Why the Tariff Outcome Matters

The Americas is Cochlear's single largest regional market, so the treatment of its products at the US border is far from trivial. Retaining duty-free status protects both the company's margins and the affordability of implants for American patients.

Had duties applied, Cochlear would have faced a choice between absorbing the cost, and pressuring its gross margin, or passing it on through higher prices, which can be difficult in a market where reimbursement levels are set by payers and government programmes.

The outcome also carries a signalling value. It reinforces the treatment of hearing implants as essential medical devices rather than discretionary goods, an important distinction as trade policy continues to evolve.

For investors, the practical effect is that one identifiable downside scenario for FY2026 and beyond has been removed, allowing attention to return to the operational drivers of the business.

The FY2025 Scorecard

The financial backdrop to the tariff news is a company still growing, though not without soft spots. In its results released on 15 August 2025, covering the year to 30 June 2025, Cochlear reported sales revenue of $2,355.8 million, up 4% (3% in constant currency).

Statutory net profit rose 9% to $388.9 million, while underlying net profit edged up 1% to $391.6 million. The board declared a total dividend of $4.30 per share, a 5% increase, split evenly between interim and final payments.

Unit growth was a highlight: cochlear implant units climbed 12% to 53,968, helped by strong adult referrals in developed markets. The Acoustics segment grew strongly, driven by uptake of the Osia system. Services revenue, by contrast, was weaker, which management attributed partly to the enduring popularity of the Nucleus 7 sound processor dampening upgrades and to cost-of-living pressures in the US.

Research and development spending reached $291.5 million, or about 12% of sales revenue, underscoring the company's reinvestment intensity. Cochlear ended the year with net cash of $275.7 million, down from the prior year as working capital and capital investment increased.

Crucially, management guided to FY2026 underlying net profit of $435-460 million, implying growth of 11-17%. Investors should treat that figure as a management target rather than a certainty, dependent on new-product uptake and market conditions.

A Large, Under-Penetrated Market

The long-term case for Cochlear rests on the sheer scale of unmet need. The company cites World Health Organization estimates that more than 430 million people globally live with disabling hearing loss, a figure expected to rise as populations age.

Against that backdrop, penetration of cochlear implants among clinically eligible adults remains low in most markets, which management has long argued leaves substantial structural room to grow. Emerging markets add a further, if more variable, layer of opportunity.

This is a genuine tailwind, but it is not automatic. Converting eligible candidates into recipients depends on clinical awareness, referral pathways and, above all, reimbursement. Growth in any given year can therefore be lumpy, and the addressable-market opportunity should be read as a multi-decade thesis rather than a near-term guarantee.

Catalysts: Smart Implants and New Processors

Cochlear's near-term momentum is closely tied to its product pipeline. In July 2025 the company received US Food and Drug Administration approval for the Nucleus Nexa system, which it describes as the world's first and only smart cochlear implant, featuring upgradeable implant firmware and internal memory that stores a recipient's hearing settings.

The ability to update an implant's firmware, in principle, allows the device to gain new features over time, a capability the company frames as an industry first. If it drives renewed interest in upgrades, it could help revive the softer Services segment.

On the Acoustics side, Cochlear announced FDA clearance for its Osia 3 sound processor in July 2026. The company describes it as the first fully rechargeable active bone conduction sound processor, offering up to 30 hours of battery life and improved sound processing, for conductive and mixed hearing loss and single-sided deafness.

Management has indicated it expects new launches, including next-generation processors, to reinvigorate upgrade cycles and support Services revenue, particularly in the second half of FY2026. Whether that materialises on the timeline suggested remains to be seen.

Risks and Uncertainties

Reimbursement is arguably the most important risk. Because implants and upgrades are largely funded by payers and health systems, changes to coverage or pricing could affect demand more than any single tariff decision.

Competition is a second factor. Cochlear operates in a concentrated market alongside a handful of global rivals, and technology leadership must be continually defended through heavy R&D spending, which itself compresses margins in the near term as new platforms and cloud systems are rolled out.

Currency movements are a persistent swing factor given the company's global revenue base and Australian cost base. Trade policy, while favourably resolved for now, also remains fluid, and future reviews or measures cannot be ruled out.

Execution risk attaches to the product transition: if new implants and processors are slower to gain traction than hoped, the Services recovery could disappoint. As with any medical-device maker, product quality and recall risk are ever-present. Finally, Cochlear typically trades on a premium valuation, which leaves limited room for operational disappointment.

A Balanced Outlook

Taken together, the picture is of a high-quality franchise entering FY2026 with a cleared trade overhang, double-digit unit growth and a refreshed product line-up, balanced against a soft Services segment, margin reinvestment and a demanding valuation.

If the Nucleus Nexa and Osia 3 launches gain traction and Services stabilises, Cochlear could progress towards its FY2026 profit guidance. If reimbursement, competition or currency move against it, the path may prove bumpier. These are possibilities, not predictions.

For investors, the tariff decision is best viewed as removing one source of uncertainty rather than as a catalyst in its own right. The core debate, over growth durability, margins and valuation, is unchanged.

Conclusion

Cochlear (ASX: COH) has secured a favourable resolution to a trade question that had lingered since early 2025, confirming that its hearing implants will keep entering the United States duty-free. That protects a key market and lets attention return to the fundamentals: unit growth, a next-generation product cycle and the vast pool of untreated hearing loss worldwide.

None of that removes the risks around reimbursement, competition and valuation, and future outcomes remain conditional. But with the tariff cloud lifted for now, Cochlear (ASX: COH) enters FY2026 with its global momentum intact and its strategy firmly in its own hands. This article is general information only and not personal financial advice.